A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

The World Health Organization (WHO) has issued new guidelines recommending the twice-yearly use of injectable lenacapavir ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

The World Health Organization now recommends lenacapavir, a twice-yearly injectable HIV prevention drug, especially for high-risk groups. This endorsement arrives amidst funding concerns, with Gilead ...

The WHO chief on Monday called on world leaders to prioritize HIV prevention and embrace meaningful partnerships in an effort ...

The World Health Organisation (WHO) has called for the immediate global rollout of a breakthrough HIV drug, lenacapavir (LEN) ...

The future of the global HIV response risks being undermined by shrinking funding and wavering political will, health leaders have warned as the International AIDS Society (IAS) Conference on HIV ...

IAS 2025, the 13th IAS Conference on HIV Science, opened today with a call to accelerate access to long-acting HIV prevention and treatment innovations amid growing global funding challenges. Four ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Increasing the use of Apretude among Black women requires not only expanding awareness of the long-acting PrEP regimen in ...

GENEVA, (CMC)-The World Health Organization (WHO) on Monday advised countries, including those in the Caribbean to ensure ...